We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+4.94%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$977M
AUM Growth
+$166M
Cap. Flow
+$154M
Cap. Flow %
15.75%
Top 10 Hldgs %
25.96%
Holding
96
New
4
Increased
44
Reduced
31
Closed
7

Top Buys

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$31.5M
2
WBA
Walgreens Boots Alliance
WBA
+$16.4M
3
INCY icon
Incyte
INCY
+$15.4M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$13.2M
5
AET
Aetna Inc
AET
+$12.5M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$13.4M
2
BIIB icon
Biogen
BIIB
+$8.24M
3
CELG
Celgene Corp
CELG
+$7.12M
4
ABMD
Abiomed Inc
ABMD
+$5.83M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$5.72M

Sector Composition

Rank Sector Weight
1 Healthcare 91.68%
2 Financials 1.43%
3 Energy 0.15%
4 Technology 0.13%
5 Communication Services 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMS
51
DELISTED
Adamas Pharmaceuticals
ADMS
$8.48M 0.87%
328,193
+118,549
+57% +$3.28M
XNCR icon
52
Xencor
XNCR
$1.55B
$8.01M 0.82%
216,443
-83,557
-28% -$2.88M
CNC icon
53
Centene
CNC
$32.5B
$8.01M 0.82%
130,000
– –
JNJ icon
54
Johnson & Johnson
JNJ
$625B
$7.28M 0.75%
+60,000
New +$7.49M
MGNX icon
55
MacroGenics
MGNX
$257M
$6.71M 0.69%
325,000
+25,000
+8% +$563K
ABBV icon
56
AbbVie
ABBV
$435B
$6.49M 0.66%
70,000
-136,700
-66% -$13.4M
REGN icon
57
Regeneron Pharmaceuticals
REGN
$80.8B
$5.87M 0.6%
17,000
-17,000
-50% -$5.32M
OMCL icon
58
Omnicell
OMCL
$1.68B
$5.79M 0.59%
110,375
+51,930
+89% +$2.44M
RVNC
59
DELISTED
Revance Therapeutics, Inc.
RVNC
$5.58M 0.57%
203,181
– –
CHRS icon
60
Coherus Oncology
CHRS
$196M
$4.9M 0.5%
350,000
– –
RIGL icon
61
Rigel Pharmaceuticals
RIGL
$750M
$4.82M 0.49%
170,328
+8,551
+5% +$304K
AERI
62
DELISTED
Aerie Pharmaceuticals
AERI
$4.73M 0.48%
70,000
+30,000
+75% +$1.68M
MDCO
63
DELISTED
Medicines Co
MDCO
$4.04M 0.41%
110,000
+10,000
+10% +$325K
BIIB icon
64
Biogen
BIIB
$30.7B
$3.77M 0.39%
13,000
-29,300
-69% -$8.24M
DPLO
65
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$3.64M 0.37%
+142,364
New +$3.32M
VRAY
66
DELISTED
ViewRay, Inc.
VRAY
$3.58M 0.37%
516,623
+184,238
+55% +$1.34M
ACAD icon
67
Acadia Pharmaceuticals
ACAD
$5.03B
$3.36M 0.34%
220,000
-50,000
-19% -$892K
ZGNX
68
DELISTED
Zogenix, Inc.
ZGNX
$2.21M 0.23%
50,000
– –
ACHN
69
DELISTED
Achillion Pharmaceuticals
ACHN
$1.75M 0.18%
617,800
-50,000
-7% -$170K
CMRX
70
DELISTED
Chimerix, Inc.
CMRX
$1.63M 0.17%
342,000
– –
PVLA
71
Palvella Therapeutics
PVLA
$2.27B
$1.52M 0.16%
3,750
– –
VIRX
72
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$907K 0.09%
12,218
-642
-5% -$57.2K
ADVM
73
DELISTED
Adverum Biotechnologies
ADVM
$816K 0.08%
15,397
+2,696
+21% +$162K
XOM icon
74
ExxonMobil
XOM
$634B
$563K 0.06%
6,804
-1,722
-20% -$137K
CVX icon
75
Chevron
CVX
$366B
$472K 0.05%
3,733
-415
-10% -$51.5K
1 2
3
4

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2018 Portfolio in Review

As of Q2 2018, Rhenman & Partners Asset Management held 96 positions worth $977M, up 20% from $811M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rhenman & Partners Asset Management deployed $154M of net new capital in Q2 2018, opening 4 new positions and adding to 44 existing holdings. Its largest new stake was Aetna Inc: 70,000 shares worth $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 95% a quarter earlier, followed by Financials and Energy.

On the sell side, the largest reduction was AbbVie, an estimated $13.4M trimmed.

  • Rhenman & Partners Asset Management's largest Q2 2018 buy was Aetna Inc: 70,000 shares worth $12.8M.
  • Rhenman & Partners Asset Management added most to Nektar Therapeutics in Q2 2018, an estimated $31.5M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2018 reduction was AbbVie, cutting an estimated $13.4M.
  • Rhenman & Partners Asset Management fully exited Endologix Inc in Q2 2018, selling an estimated $3.83M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 26% of its $977M portfolio in Q2 2018.
  • Rhenman & Partners Asset Management opened 4 new positions and closed 7 in Q2 2018.
  • Rhenman & Partners Asset Management's portfolio value rose 20% quarter-over-quarter to $977M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2018, filed 20 Jul 2018.